Blood in the water.

What does hypofractionation of prostate radiation have to offer beyond convenience? The theory is it can offer an increased therapeutic window assuming the long-cited low α/β ratio for prostate cancer is lower than that of nearby organs at risk. CHHiP is back to offer more insight on the realized impact of prostate hypofractionation on patient-reported toxicity—last time GI was the focus, this time GU. Unfortunately, it doesn’t appear hypofractionation is cracking open the therapeutic window as much as hoped since α/β ratios fit to late toxicities were low, ranging from 0.6 for hematuria to 2 Gy for dysuria, much lower than historic estimates ranging from 3-5. | Brand, Int J Radiat Oncol Biol Phys 2022